Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)

China · Delayed Price · Currency is CNY

3.390

0.00 (0.00%)

Jul 29, 2026, 3:04 PM CST

-17.72% (1Y)

Market Cap	10.18B -17.7%
Revenue (ttm)	4.68B -18.1%
Net Income	23.88M +0.9%
EPS	0.01 +14.4%
Shares Out	3.00B
PE Ratio	272.11
Forward PE	24.21
Dividend	0.01 (0.29%)
Ex-Dividend Date	Jul 15, 2026

Volume	58,212,539
Open	3.430
Previous Close	3.390
Day's Range	3.360 - 3.430
52-Week Range	2.820 - 4.490
Beta	0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About SHE:300026

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and sale of various pharmaceutical products in China. The company offers traditional Chinese medicine formula granules; finished drugs, including xuebijing injections, low molecular weight heparin calcium injections, moxifloxacin hydrochloride sodium chloride injections, enoxaparin sodium injections, nadronexacin calcium injections, fasudil hydrochloride injections, ketorheic acid tromethamine injections, ibanoxetine sodium injections, Qingfei Sanjie pill... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1996

Employees 4,852

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300026

Full Company Profile

Financial Performance

In 2025, SHE:300026's revenue was 4.94 billion, a decrease of -14.55% compared to the previous year's 5.78 billion. Earnings were 18.50 million, a decrease of -13.85%.

Financial Statements